cardiovascular variables were measured after incremental doses of nalbuphine , up to 2 or 3 mg/kg in fourteen patients with coronary artery disease with normal left ventricular function and in seven patients with mitral valve disease .
C0007226
cardiovascular
C0026265
mitral valve